Target Name: CHGA
NCBI ID: G1113
Review Report on CHGA Target / Biomarker Content of Review Report on CHGA Target / Biomarker
CHGA
Other Name(s): SS-18 | chromofungin | Parastatin | CMGA_HUMAN | Pituitary secretory protein I | Chromogranin A, transcript variant 1 | parathyroid secretory protein 1 | GR-44 | pituitary secretory protein I | WA-8 | Serpinin-RRG | SP-I | ER-37 | Vasostatin-1 | Vasostatin I | Chromogranin-A (isoform 1) | Serpinin | Chromogranin-A | Vasostatin-2 | CgA | Parathyroid secretory protein 1 | chromogranin A | GV-19 | Vasostatin II | catestatin | AL-11 | CHGA variant 1 | betagranin (N-terminal fragment of chromogranin A) | EA-92 | CGA | Vasostatin | ES-43 | SL21 | PHE5 | PHES | LF-19 | WE-14 | p-Glu serpinin precursor | Catestatin | GE-25 | Pancreastatin

CHGA: A Non-Code RNA Molecule Regulator of Genes and Chromatin

CHGA (CHromosome-Writable Account) is a non-coding RNA molecule that is expressed in most tissues of the body. It is a key regulator of gene expression and has been implicated in a variety of cellular processes, including DNA replication, transcription, and chromatin remodeling. CHGA has also been shown to play a role in the development and progression of various diseases, including cancer.

One of the key features of CHGA is its ability to interact with DNA. It has been shown to form a complex with DNA-protein complexes, which are responsible for regulating gene expression and DNA replication. These interactions between CHGA and DNA-protein complexes are critical for the regulation of gene expression and are likely to be involved in the development of many diseases.

Another important function of CHGA is its role in chromatin remodeling. Chromatin remodeling is the process by which the DNA in a cell is organized into a more compact and ordered structure. This process is important for the regulation of gene expression and is also involved in the development of various diseases, including cancer.

CHGA has also been shown to play a role in the regulation of cell cycle progression. The cell cycle is the process by which a cell grows and replicates its genetic material. CHGA has also been shown to regulate the length and progression of the cell cycle, which is important for the development and progression of various diseases.

In addition to its role in the regulation of the cell cycle, CHGA has also been shown to play a role in the regulation of cell death. Cell death, also known as apoptosis, is a natural process that helps maintain the health and function of a cell. However, in the case of cancer, abnormal cell death can contribute to the development and progression of the disease. CHGA has been shown to regulate cell death, which may be an important target for the development of cancer therapies.

CHGA has also been shown to play a role in the regulation of tissue repair and regeneration. Tissue repair and regeneration are important processes that help repair damaged tissue and promote the growth and development of new tissues. CHGA has also been shown to regulate these processes, which may be important for the development of tissues that are important for repair and regeneration.

In conclusion, CHGA is a non-coding RNA molecule that plays a critical role in the regulation of gene expression, chromatin remodeling, cell cycle progression, cell death, and tissue repair and regeneration. Its functions as a drug target or biomarker make it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of CHGA in disease and to develop effective treatments.

Protein Name: Chromogranin A

Functions: Strongly inhibits glucose induced insulin release from the pancreas

The "CHGA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHGA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CHGB | CHI3L1 | CHI3L2 | CHIA | CHIAP1 | CHIAP2 | CHIC1 | CHIC2 | CHID1 | CHIT1 | CHKA | CHKB | CHKB-CPT1B | CHKB-DT | CHL1 | CHL1-AS2 | Chloride channel | CHM | CHML | CHMP1A | CHMP1B | CHMP1B2P | CHMP2A | CHMP2B | CHMP3 | CHMP4A | CHMP4B | CHMP4BP1 | CHMP4C | CHMP5 | CHMP6 | CHMP7 | CHN1 | CHN2 | CHN2-AS1 | CHODL | Cholesterol Epoxide Hydrolase (ChEH) | Cholesterol esterase | Choline transporter-like protein | CHORDC1 | CHORDC1P4 | CHP1 | CHP1P2 | CHP2 | CHPF | CHPF2 | CHPT1 | CHRAC1 | CHRD | CHRDL1 | CHRDL2 | CHRFAM7A | CHRM1 | CHRM2 | CHRM3 | CHRM3-AS2 | CHRM4 | CHRM5 | CHRNA1 | CHRNA10 | CHRNA2 | CHRNA3 | CHRNA4 | CHRNA5 | CHRNA6 | CHRNA7 | CHRNA9 | CHRNB1 | CHRNB2 | CHRNB3 | CHRNB4 | CHRND | CHRNE | CHRNG | Chromobox protein homolog | Chromodomain Helicase DNA Binding Protein | Chromosome 10 open reading frame 115 | Chromosome 16 open reading frame 47 | Chromosome 17 open reading frame 47 | Chromosome 6 open reading frame 183 | CHROMR | CHST1 | CHST10 | CHST11 | CHST12 | CHST13 | CHST14 | CHST15 | CHST2 | CHST3 | CHST4 | CHST5 | CHST6 | CHST7 | CHST8 | CHST9 | CHSY1 | CHSY3 | CHTF18 | CHTF8